Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2016

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2016
Published Jul 30, 2016
49 pages — Published Jul 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2016, provides in depth analysis on Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted pipeline therapeutics.

The report provides comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
- The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics

Reasons to buy

- Gain strategically

  
Source:
Document ID
GMDHC0428TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Overview71
Therapeutics Development83
  Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Products under Development by Stage of Development81
  Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Products under Development by Therapy Area91
  Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Products under Development by Indication101
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Pipeline Products Glance111
  Early Stage Products111
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Products under Development by Companies122
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Products under Development by Universities/Institutes142
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Therapeutics Assessment167
  Assessment by Monotherapy/Combination Products161
  Assessment by Mechanism of Action172
  Assessment by Route of Administration192
  Assessment by Molecule Type212
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Companies Involved in Therapeutics Development236
  AstraZeneca Plc231
  Neurimmune Holding AG241
  Nordic Bioscience A/S251
  Novo Nordisk A/S261
  reMYND NV271
  Zealand Pharma A/S281
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drug Profiles2914
  (insulin human + pramlintide acetate) Drug Profile291
  AM-833 Drug Profile301
  KBP-042 Drug Profile312
  KBP-056 Drug Profile331
  NI-203 Drug Profile341
  ReS-13I Drug Profile351
  ReS-39I Drug Profile361
  Salmon Calcitonin Drug Profile372
  Synthetic Peptides to Target IAPP for Obesity and Diabetes Drug Profile391
  UGP-302 Drug Profile402
  ZP-4982 Drug Profile421
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Dormant Projects431
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Discontinued Products441
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Featured News &Press Releases453
  Jun 08, 2016: Zealand presents new data on proprietary preclinical peptide drug candidates at the 76th Annual American Diabetes Associations Scientific Sessions451
  May 05, 2014: reMYND s novel diabetes treatment prevents and even reverses disease progression in pre-clinical diabetes models451
  Aug 15, 2012: Unigene Labs And Nordic Bioscience Announce Preliminary Selection Of Lead Compound For Treatment Of Type 2 Diabetes462
Appendix482
  Methodology481
  Coverage481
  Secondary Research481
  Primary Research481
  Expert Panel Validation481
  Contact Us481
  Disclaimer491

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2016" Jul 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Islet-Amyloid-Polypeptide-Amylin-or-Diabetes-Associated-Peptide-or-Insulinoma-Amyloid-Peptide-or-IAPP-Pipeline-Review-H2-2016-2088-16326>
  
APA:
Global Markets Direct - Market Research. (2016). Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2016 Jul 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Islet-Amyloid-Polypeptide-Amylin-or-Diabetes-Associated-Peptide-or-Insulinoma-Amyloid-Peptide-or-IAPP-Pipeline-Review-H2-2016-2088-16326>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.